Rustenbeck I, Herrmann C, Ratzka P, Hasselblatt A
Institute of Pharmacology and Toxicology, University of Göttingen, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):410-7. doi: 10.1007/pl00005070.
To elucidate the beta-cytotropic effect of imidazoline compounds their inhibitory effect on ATP-dependent K+ channels (K(ATP) channels) in pancreatic B-cells was compared with their binding to membranes from insulin-secreting HIT T15 cells. K(ATP) channels in inside-out patches from B-cells were closed with the following rank order of efficacy at 10 microM: guanabenz > phentolamine = alinidine > clonidine > idazoxan > rilmenidine = amiloride. The last four compounds achieved an incomplete inhibition only. In contrast to sulfonylureas, the inhibitory action of imidazolines was not enhanced by ADP. With intact cells the site which mediates inhibition is less easily accessible for protonated compounds, suggesting a location at the inner face of the plasma membrane. Competition binding experiments were performed by masking alpha-adrenoceptors and using [3H]clonidine as ligand. Homologous displacement of [3H]clonidine revealed two distinct binding sites in HIT cell membranes characterized by dissociation constants of 38 nM and 4,911 nM and maximal binding capacities of 118 fmol/mg protein and 18 pmol/mg protein. Generally, ligands for I2 imidazoline receptors were more potent than ligands for I1 imidazoline receptors to displace [3H]clonidine from the high affinity site, which does not fit into the current classification of imidazoline receptors. Binding to the second site had affinities in the micromolar range, similar to the concentrations necessary to inhibit K(ATP) channels in B-cells. However, alinidine and phentolamine inhibited K(ATP) channels already at concentrations at which they displaced [3H]clonidine only from the high affinity site, but not yet from the low affinity site. Since the proportion of the low and high affinity site varied in dependence of the competitor, the imidazoline binding sites in HIT cells may not be independent, but may rather represent two interacting or interconvertible sites both of which may be involved in K(ATP) channel closure.
为阐明咪唑啉化合物的β细胞otropic作用,将它们对胰腺β细胞中ATP依赖性钾通道(K(ATP)通道)的抑制作用与其与胰岛素分泌性HIT T15细胞膜的结合情况进行了比较。β细胞内向外膜片中的K(ATP)通道在10微摩尔浓度下按以下效力顺序关闭:胍那苄>酚妥拉明=阿利尼定>可乐定>伊达唑胺>利美尼定=阿米洛利。最后四种化合物仅实现了不完全抑制。与磺脲类药物不同,咪唑啉的抑制作用不会因ADP而增强。对于完整细胞,介导抑制作用的位点对于质子化化合物来说较难接近,这表明其位于质膜的内表面。通过掩盖α肾上腺素能受体并使用[3H]可乐定作为配体进行了竞争结合实验。[3H]可乐定的同源置换揭示了HIT细胞膜中有两个不同的结合位点,其解离常数分别为38 nM和4911 nM,最大结合容量分别为118 fmol/mg蛋白和18 pmol/mg蛋白。一般来说,I2咪唑啉受体的配体比I1咪唑啉受体的配体更有效地从高亲和力位点置换[3H]可乐定,这不符合目前咪唑啉受体的分类。与第二个位点的结合亲和力在微摩尔范围内,类似于抑制β细胞中K(ATP)通道所需的浓度。然而,阿利尼定和酚妥拉明在仅从高亲和力位点而非低亲和力位点置换[3H]可乐定的浓度下就已经抑制了K(ATP)通道。由于低亲和力和高亲和力位点的比例因竞争者而异,HIT细胞中的咪唑啉结合位点可能不是独立的,而可能代表两个相互作用或可相互转化的位点,两者都可能参与K(ATP)通道的关闭。